Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years
This analysis provides information about the long-term safety of upadacitinib in AD, with no new important safety signals identified for up to 6 years.
Authors
- Andrew M. Platt
- Jonathan I. Silverberg (ORCID: https://orcid.org/0000-0003-3686-7805)
- Deanne M. Dilley
- Henrique D. Teixeira (ORCID: https://orcid.org/0000-0001-5488-3556)
- Christopher G. Bunick (ORCID: https://orcid.org/0000-0002-4011-8308)
- Elvira D’Andrea (ORCID: https://orcid.org/0000-0002-5263-3964)
- Emma Guttman‐Yassky (ORCID: https://orcid.org/0000-0002-9363-324X)
- Namita Vigna
- Norito Katoh (ORCID: https://orcid.org/0000-0002-3498-2482)
- Xing‐Hua Gao (ORCID: https://orcid.org/0000-0001-8809-8564)
- Gweneth F. Levy
- Alan D. Irvine (ORCID: https://orcid.org/0000-0002-9048-2044)
- Stephan Weidinger (ORCID: https://orcid.org/0000-0003-3944-252X)
- Mona Shahriari (ORCID: https://orcid.org/0000-0002-1191-7557)
Institutions
- Kyoto Prefectural University (JP)
- George Washington University (US)
- Trinity College Dublin (IE)
- AbbVie (United States) (US)
- Yale University (US)
- Kyoto Prefectural University of Medicine (JP)
- University Hospital Schleswig-Holstein (DE)
- First Hospital of China Medical University (CN)
- Bupa Cromwell Hospital (GB)
- China Medical University (CN)
- University of Lübeck (DE)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2025-11-15
- DOI
- https://doi.org/10.1111/jdv.70172
- Citations
- 3
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 6.01